Track Journey Medical Corporation Common Stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Journey Medical Corporation Common Stock DERM · Stock Open Journey Medical Corporation Common Stock in new tab

4.33 USD
EPS
-0.22
P/B
3.89
ROE
-23.77
Beta
1.15
Target Price
13.75 USD
Loading chart...
Key Metrics
Earnings dateMarch 24, 2027
EPS-0.22
Book Value1.16
Price to Book3.89
Debt/Equity79.53
% Insiders31.753%
Growth
Revenue Growth0.23%
Estimates
Forward P/E-75.33
Forward EPS-0.06
Target Mean Price13.75

DCF valuation

Model fair value for Journey Medical Corporation Common Stock (DERM)
Result
Sign in to run the valuation for DERM.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
4 analysts · consensus Strong buy · mean target 13.75 USD (low 13.00, high 15.00) · as of 10 Nov 2026
Low 13.00
Mean 13.75
High 15.00
Price 4.33
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Journey Medical Corporation Common Stock Logo Journey Medical Corporation Common Stock Analysis (DERM)

United States Health Care Official Website Stock

Is Journey Medical Corporation Common Stock a good investment? Journey Medical Corporation Common Stock (DERM) is currently trading at 4.33 USD. Market analysts have a consensus price target of 13.75 USD. This suggests a potential upside from current levels.

Earnings Schedule: Journey Medical Corporation Common Stock is expected to release its next earnings report on March 24, 2027. The market consensus estimate for Forward EPS is -0.06.

Investor FAQ

Does Journey Medical Corporation Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is Journey Medical Corporation Common Stock?

Journey Medical Corporation Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 24, 2027. The company currently has a trailing EPS of -0.22.

Company Profile

Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also provides Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Emrosi for the treatment of inflammatory lesions of rosacea; Exelderm cream and solution for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.

Exchange Ticker
NMS (United States) DERM
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion